(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for Robert Easton�
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 36.94 - 56.47
Open     -
Vol / Avg. 0.00/574,682.00
Mkt cap 3.83B
P/E     -
Div/yield     -
EPS -0.53
Shares 70.48M
Beta 0.94
Inst. own 107%
Jan 28, 2015
Q4 2014 Cepheid Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 14, 2015
Cepheid at JPMorgan Healthcare Conference - 1:30PM EST - Add to calendar
Dec 11, 2014
Cepheid at Oppenheimer Healthcare Conference
Dec 2, 2014
Cepheid at NASDAQ OMX Investor Program
Oct 16, 2014
Q3 2014 Cepheid Earnings Call - Webcast
Oct 16, 2014
Q3 2014 Cepheid Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -6.28% -4.48%
Operating margin -2.95% -3.99%
EBITD margin - 3.67%
Return on average assets -3.83% -4.95%
Return on average equity -8.11% -6.74%
Employees 1,200 -
CDP Score - -


904 Caribbean Drive
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market. The Company�s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company�s two principal systems are the GeneXpert and SmartCycler. The GeneXpert system, its primary offering in the Clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors� offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew D. Miller CPA Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Philippe Jacon President - High Burden Developing Country Business
Age: 54
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Chief Operating Officer, Principal Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
David H. Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Age: 54
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Corporate Development, General Counsel
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Farrell Executive Vice President - International Commercial Operations
Bio & Compensation  - Reuters
Mike Fitzgerald Executive Vice President, Global Human Resources
Age: 54
Bio & Compensation  - Reuters
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 68
Bio & Compensation  - Reuters